These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28591284)

  • 1. Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration.
    Sugimoto MAA; Toledo VPCP; Cunha MRR; Carregal VM; Jorge R; Leão P; Fialho SL; Silva-Cunha A
    Arq Bras Oftalmol; 2017; 80(2):108-113. PubMed ID: 28591284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Storage stability of bevacizumab in polycarbonate and polypropylene syringes.
    Khalili H; Sharma G; Froome A; Khaw PT; Brocchini S
    Eye (Lond); 2015 Jun; 29(6):820-7. PubMed ID: 25853399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-molecular-weight aggregates in repackaged bevacizumab.
    Kahook MY; Liu L; Ruzycki P; Mandava N; Carpenter JF; Petrash JM; Ammar DA
    Retina; 2010 Jun; 30(6):887-92. PubMed ID: 20458261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab.
    Crul M; Zandvliet A; Moes JR; Veenbaas T; Smeets O
    J Ocul Pharmacol Ther; 2019; 35(6):372-375. PubMed ID: 31259653
    [No Abstract]   [Full Text] [Related]  

  • 5. CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
    Schargus M; Werner BP; Geerling G; Winter G
    Retina; 2018 Oct; 38(10):2088-2095. PubMed ID: 28841584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS.
    Peterson JS; Rockwell K; Scott IU; Ip MS; VanVeldhuisen PC; Blodi BA;
    Retina; 2019 Sep; 39(9):1802-1809. PubMed ID: 29746405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months.
    Chen YH; Wu PC; Shiea J; Lo LH; Wu YC; Kuo HK
    J Ocul Pharmacol Ther; 2009 Feb; 25(1):65-9. PubMed ID: 19232008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration.
    Paul M; Vieillard V; Roumi E; Cauvin A; Despiau MC; Laurent M; Astier A
    Ann Pharm Fr; 2012 May; 70(3):139-54. PubMed ID: 22655582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of compounded bevacizumab prepared for intravitreal injection.
    Yannuzzi NA; Klufas MA; Quach L; Beatty LM; Kaminsky SM; Crystal RG; D'Amico DJ; Kiss S
    JAMA Ophthalmol; 2015 Jan; 133(1):32-9. PubMed ID: 25233052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure.
    Akbas S; Sahin A; Calis S; Oncel H; Capan Y
    Pharmazie; 2018 Jul; 73(7):369-374. PubMed ID: 30001769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of compounded bevacizumab with postinjection endophthalmitis.
    VanderBeek BL; Bonaffini SG; Ma L
    JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions.
    Signorello L; Pucciarelli S; Bonacucina G; Polzonetti V; Cespi M; Perinelli DR; Palmieri GF; Pettinari R; Pettinari C; Fiorentini G; Vincenzetti S
    Curr Pharm Biotechnol; 2014; 15(2):113-9. PubMed ID: 24953231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
    Lode HE; Gjølberg TT; Foss S; Sivertsen MS; Brustugun J; Andersson Y; Jørstad ØK; Moe MC; Andersen JT
    Sci Rep; 2019 Dec; 9(1):18021. PubMed ID: 31792234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of bevacizumab compounded for intravitreal administration.
    Palmer JM; Amoaku WM; Kamali F
    Eye (Lond); 2013 Sep; 27(9):1090-7. PubMed ID: 23788205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of Cell-Penetrating Peptide anti-VEGF Formulations for the Treatment of Age-Related Macular Degeneration.
    Nikoi ND; Berwick M; Bryant JA; Riordan L; Slope L; Peacock AFA; de Cogan F
    Curr Eye Res; 2021 May; 46(5):751-757. PubMed ID: 33896277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab.
    Das T; Volety S; Ahsan SM; Thakur AK; Sharma S; Padhi TR; Basu S; Rao ChM
    Clin Exp Ophthalmol; 2015 Jul; 43(5):466-73. PubMed ID: 25545882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases.
    Liu J; Li S; Li G; Li X; Yu C; Fu Z; Li X; Teng L; Li Y; Sun F
    Int J Pharm; 2019 May; 563():228-236. PubMed ID: 30959236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab.
    Schargus M; Kopp KT; Helbig C; Frings A; Winter G
    Transl Vis Sci Technol; 2021 Aug; 10(9):21. PubMed ID: 34406342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.
    Liu L; Ammar DA; Ross LA; Mandava N; Kahook MY; Carpenter JF
    Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):1023-34. PubMed ID: 21051703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.